Weight loss drugs can help employers cut health care costs, study saysByCatherine ArnstUpdatedWednesday 10:28AM
Hims & Hers strikes a deal with Novo Nordisk to sell Wegovy — and the stock soars 28%ByKevin RyanPublishedApril 29, 2025
Eli Lilly is stepping up its fight against copycat weight loss drugsByCatherine ArnstPublishedApril 23, 2025
Roche says it will invest $50 billion in the U.S. as tariff fears hit pharmaByCatherine ArnstPublishedApril 22, 2025
Eli Lilly's weight loss pill could be just as good as Ozempic — and the stock soarsByShannon CarrollPublishedApril 17, 2025
Hims & Hers stock slipped as investors were left unimpressed with its new weight-loss drug optionsByBruce GilPublishedApril 2, 2025
Novo Holdings' earnings nearly doubled in 2024, despite Novo Nordisk's stock slumpByBruce GilPublishedApril 2, 2025
Here's how much Ozempic and similar drugs have soared in popularity since 2018ByBruce GilPublishedApril 1, 2025
Moderna and other vaccine stocks fall after a top FDA official quitsByBruce GilPublishedMarch 31, 2025
Eli Lilly's Alzheimer's drug is rejected by EU regulators over brain swelling risk, despite U.S. approvalByBruce GilPublishedMarch 28, 2025
Cheaper Wegovy, 23andMe shutters, and RFK Jr. cuts FDA jobs: Pharma news roundupByBruce GilPublishedMarch 28, 2025
Wegovy sales took a hit this year. Novo's CEO blames off-brand competitionByBruce GilPublishedMarch 27, 2025
RFK Jr. plans to cut 3,500 jobs at the FDA, as staff is reportedly already struggling with workloadByBruce GilPublishedMarch 27, 2025
Eli Lilly's online health platform just expanded beyond weight loss to tackle Alzheimer’sByBruce GilPublishedMarch 27, 2025
GLP-1s are driving returns on R&D investments for Big Pharma, report saysByBruce GilPublishedMarch 25, 2025
